2026-02-28 02:55Company and Industry Summary Company: Zai Lab Key Financial Performance - 4Q total revenue increased by 17% year-over-year to $127.6 million, with FY25 revenue growing by 15% to $460.2 million [1] - Adjusted operating loss narrowed by 25% year-over-year, indicating improved operational efficiency [1] - Research and development (R&D) and sales expenses as a percentage of revenue decreased compared to 2024 [1] - Year-end cash reserves were robust, reaching $789.6 million [1] Clinical Development Highlights - Zoci: Global registration clinical trials for 2/3L SCLC are progressing rapidly, with three major data catalysts expected in 2026: intracranial efficacy for 2L+ SCLC, data for extra-pulmonary NEC, and 1L SCLC combination data (+PD-L1 ± chemotherapy) [1] - ZL-1503 (IL-13/IL-31Rα): Global Phase 1/1b trial is ongoing, with first human data expected in 2H26 [1] - ZL-6201 (LRRC15 ADC): Phase 1 trial has been initiated and is continuing to enroll participants [1] - ZL-1222 (PD-1/IL-12): Preclinical data updates are expected in 1H26, with IND application research anticipated to be completed within 2026 [1] - ZL-1311 (MUC17 TCE): IND application is expected to be completed by the end of 2026 [1] - Zai Lab is systematically laying out TCE and exploring additional immune cell factor directions beyond IL-12, with more details to be disclosed throughout the year [1] Company: Eiger BioPharmaceuticals Product Development and Market Strategy - Eiger is focused on increasing penetration and duration of therapy (DOT) for gMG and CIDP patients with its IV/SC formulations [2] - KarXT is set to be commercially launched in China in 2Q26, with preparations underway for 2027 insurance access [2] - Povetacicept and Elegrobart are expected to have critical data readouts for IgAN and TED in 1H26 [2] - Zoci (DLL3 ADC): Anticipated data for small lung intracranial and NEC in 1H26, with 1L SCLC registration clinical trials and new MOA combination clinical trials starting in 2026 [2] - ZL-1503 (IL-13/IL-31Rα): First human data is expected in 2026, focusing on pharmacokinetics, pharmacodynamics, and biomarker data in healthy subjects [2] - KarXT (schizophrenia) is set for launch; TIVDAK (cervical cancer) and TTFields (pancreatic cancer) are also being introduced in China [2]